LL-37 Peptide For Sale

Buy LL-37 peptide: 5mg or 10mg listed purchase quantities. Compare live prices across 8 listed vendors with real cost per mg, recorded COA availability and discount codes.

Buy LL-37 peptide starting at $33.15/purchase from 8 listed vendors. Compare 5mg and 10mg purchase quantity options by cost per mg, price per purchase, monthly cost, discount codes and recorded COA metadata (not independent verification).

About LL-37

In clinical trialsAlso known as: Cathelicidin · hCAP-18 · CAMP

LL-37 is a 37-residue human cathelicidin peptide — the body's only cathelicidin — most often sourced for antimicrobial, wound-healing, and immune research. It works as both a broad-spectrum antimicrobial and an immune-signaling molecule. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1][2]

What to check before you buy LL-37:

  • A third-party COA showing ≥98% purity by HPLC plus mass-spec confirmation of the 37-residue sequence.
  • A COA dated within the last 6–12 months that matches the exact vial size and batch you are buying.
  • Accurate vial fill matching the label; under-filled vials are a common failure mode that skews reconstitution math.

Topical and parenteral LL-37 has been investigated in chronic wound healing, venous leg ulcers (Gronberg et al., Phase 2 randomised trial reported accelerated healing), inflammatory skin conditions, and adjunct antimicrobial therapy for antibiotic-resistant infections.[3][4] LL-37 has also been studied as a biomarker in vitamin-D-dependent host defence and in the pathophysiology of psoriasis and rosacea where it can drive autoinflammation.[5] No FDA-approved LL-37 drug product exists, though it is in active early-stage clinical development.[6]

Regulatory: Not FDA-approved. Phase 1–2 clinical work in wound healing and topical infection (notably the Gronberg ulcer trials). Research-grade material for non-clinical use; no chronic systemic-use human safety data exists.

Read the full mechanism & research breakdown

LL-37: Mechanisms, Half-Life & Research Data

A skimmable deep dive into how LL-37 works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.

How it works

LL-37 is the active 37-residue C-terminal fragment of hCAP-18 (encoded by the CAMP gene on chromosome 3), produced by proteolytic cleavage of the cathelin-domain pro-peptide stored in the secondary granules of neutrophils and in the lysosomes of keratinocytes, mast cells, and several mucosal epithelia. It is the only cathelicidin in the human innate immune system and is the foundational characterised molecule in a peptide class that includes many vertebrate and animal cathelicidins.[1][2] The molecule's pharmacology has two distinct arms. The antimicrobial arm is biophysical: LL-37 folds into an amphipathic α-helix on contact with anionic surfaces, inserts into the negatively charged outer leaflet of bacterial membranes (which display LPS and anionic phospholipids absent from mammalian outer-membrane leaflets), and disrupts membrane integrity via either toroidal-pore or carpet-model mechanisms — killing Gram-positive bacteria, Gram-negative bacteria, fungi, and enveloped viruses across a broad spectrum.[1][2] The immunomodulatory arm is signalling-mediated: LL-37 binds FPR2/ALX on neutrophils, monocytes, mast cells, and endothelial cells to drive chemotaxis, modulate cytokine release, promote keratinocyte migration, induce angiogenesis, and recruit progenitor cells to wounds — the basis for its established role in cutaneous host defence and wound repair.[2][3] Expression of the CAMP gene is induced by 1,25-dihydroxyvitamin D3 via a vitamin D receptor response element, which is the molecular basis for the vitamin-D / innate-immunity axis.[7] In some inflammatory skin diseases (notably rosacea and psoriasis), dysregulated cathelicidin processing produces LL-37 fragments that drive autoinflammation rather than host defence — useful context for understanding both the therapeutic potential and the inflammatory-side-effect profile.[5]

Active research areas

  • Chronic wound healing — venous leg ulcers (Phase 2)
    The Gronberg 2014 randomised placebo-controlled trial in hard-to-heal venous leg ulcers showed that topical LL-37 was safe and accelerated healing — the strongest clinical readout for LL-37 to date and the basis for ongoing wound-healing development.[3]
  • Topical antimicrobial therapy and antibiotic-resistant infection
    LL-37 is in active early-phase clinical development as a topical or locally applied antimicrobial for indications where broad-spectrum activity and slow resistance development matter — notably wound and burn infections, with multiple Phase 1/2 studies registered.[6][4]
  • Inflammatory skin disease (rosacea, psoriasis)
    Cathelicidin pathway dysregulation contributes to the pathophysiology of rosacea and psoriasis;[5] research-grade exogenous LL-37 is not used therapeutically in these conditions, and the cathelicidin pathway is more typically a drug target to modulate downward than upward in these settings.
  • Vitamin D / innate-immunity axis
    CAMP gene transcription is directly induced by vitamin D via VDR;[7] this provides the molecular basis for the vitamin-D / innate-immune-defence interaction and for the observed link between vitamin D status and infection susceptibility.
Open questions & leading hypotheses (1)
  • Hypothesis: Systemic administration of LL-37 would be a useful adjunct or alternative to antibiotics for multidrug-resistant infections.
    Evidence: The mechanism (membrane disruption) is biophysical and largely independent of bacterial protein targets, which slows the evolution of resistance compared to most antibiotic classes; broad-spectrum activity across Gram-positive, Gram-negative, fungal, and enveloped-viral targets is established in vitro.[1][2][4] Counter-evidence: LL-37 is rapidly degraded by mammalian proteases in plasma, limiting systemic exposure; it can be cytotoxic to mammalian cells at higher concentrations and drive inflammatory side effects in skin and mucosal contexts;[5] all clinical development to date has been topical or locally applied rather than systemic, reflecting these constraints; the chronic systemic-use safety profile is essentially uncharacterised.
What community users report

Anecdotal — not controlled-trial evidence

On r/Peptides, LL-37 is discussed in the small but persistent "antimicrobial peptide" niche, typically framed as a research-grade peptide for Lyme disease, chronic infection, and biofilm-associated conditions, with subcutaneous or nebulised protocols of 100–500 µg/day for short cycles.[8] Users report subjective improvements in inflammatory symptoms; some threads warn of injection-site reactions and transient flu-like symptoms consistent with the immunomodulatory mechanism. **These reports are anecdotal and have not been validated in human controlled trials of systemic LL-37; the only published Phase 2 efficacy data is for topical use in venous leg ulcers;[3] LL-37 is not FDA-approved for any indication;[6] and the chronic systemic-use safety profile is uncharacterised.**

Sources & references (8)

Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.

  1. [1]Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 2004;75:39–48. · PMID: 12960280 link
  2. [2]Vandamme D et al. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol 2012;280:22–35. · PMID: 23246832 link
  3. [3]Gronberg A et al. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen 2014;22:613–621. · PMID: 25041740 link
  4. [4]Mahlapuu M et al. Antimicrobial peptides: an emerging category of therapeutic agents. Front Cell Infect Microbiol 2016;6:194 — review of clinical-stage AMPs including LL-37. · PMID: 28083516 link
  5. [5]Yamasaki K et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007;13:975–980 — cathelicidin in rosacea pathophysiology. · PMID: 17676051 link
  6. [6]ClinicalTrials.gov search "LL-37 OR cathelicidin", accessed May 2026 — multiple Phase 1/2 wound-healing and topical-infection studies. link
  7. [7]Gombart AF et al. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor. FASEB J 2005;19:1067–1077 — vitamin D / cathelicidin axis. · PMID: 15985530 link
  8. [8]Community report — r/Peptides LL-37 discussion threads (subreddit), accessed May 2026. link

What LL-37 Costs Right Now

WPA currently tracks LL-37 from 8 distinct vendors across 9 separate LL-37 listings. In-stock LL-37 vials run from $33.15 to $80.75 — a 2.4x spread for the same compound. Peptira holds the lowest sticker price at $33.15. Normalized to milligrams, LL-37 costs $4.45/mg to $14.25/mg on this page. The best per-milligram value is the listed 10 mg purchase quantity from Ascension Peptides.

LL-37 is stocked in 2 sizes: 10 mg listed quantity; vial count not recorded; 5 mg listed quantity; vial count not recorded. Because vials of different strengths rarely scale linearly in price, the per-milligram column is the only fair way to rank them.

Ranked by true cost per milligram, the LL-37 listings WPA tracks are: Ascension Peptides — 10mg at $44.50 ($4.45/mg), COA purity 99.94%; Peptira — 5mg at $33.15 ($6.63/mg), COA purity 99.93%; EZ Peptides — 10mg at $70.20 ($7.02/mg), COA purity 99.50%; Ameano Peptides — 10mg at $72 ($7.20/mg), COA purity 99.50%; Paramount Peptides — 10mg at $80.75 ($8.07/mg), COA purity 99.08%.

LL-37 COA Coverage Across Tracked Vendors

8 of the 9 tracked LL-37 listings (89%) are marked as having COA availability in WPA's listing data; this marker is not independent verification. A purity value is recorded for 8 listings; purity alone does not establish identity or independent testing. The recorded purity values range from 99.08% to 99.94%. 7 listings record more LL-37 in the vial than the label claims; check the vendor's report and batch before drawing conclusions. The latest COA date recorded in WPA's listing data is 8/26.

To assess a COA, inspect the actual report for the independent lab, test date, and a batch and vial size matching the LL-37 offer. WPA's listing fields do not establish that a report was independently verified.

LL-37 Calculator Input Observations

In lifetime LL-37 calculator inputs, 200mcg is the most frequent entered amount (23 of 98 runs). Separately, Daily (7x/wk) is the most frequent overall cadence (4 of 18 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 200mcg, 5x/week is most frequent (3 of 11 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. As nominal quantity arithmetic only, 10 mg of listed product divided by 0.2 mg gives roughly 50 portions before preparation losses. This does not establish vial count, stability after preparation, or cycle length.

LL-37 Discount Codes

9 of the 9 tracked LL-37 listings carry a WPA researcher discount code. The largest live discount is 50% off. Every price and per-milligram figure on this page is the post-discount number, so you are never comparing a discounted listing against an undiscounted one. Codes change and some exclude sale items or carry order minimums.

About LL-37

LL-37 is a 37-residue human cathelicidin peptide — the body's only cathelicidin — most often sourced for antimicrobial, wound-healing, and immune research. It works as both a broad-spectrum antimicrobial and an immune-signaling molecule. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.

LL-37 is tracked under the Skin Peptides category on WPA. Its reported half-life is ~30–60 min. Calculator inputs do not establish why a cadence was selected or validate a protocol. Not FDA-approved.

How to Read the LL-37 Comparison

  • Price per milligram — Every LL-37 listing is normalized to $4.45/mg-style unit pricing, so a small cheap vial cannot hide a worse real cost than a larger one.
  • COA metadata and purity — 8 LL-37 listings are marked for COA availability, and 8 have a recorded purity value. These fields do not independently verify a report.
  • Vials sizes — The LL-37 comparison includes 5mg and 10mg listed purchase quantities. Check package composition separately.
  • Stock status — Live in-stock state for each LL-37 listing, refreshed on a recurring basis.

Frequently Asked Questions: LL-37

Is it legal and safe to buy LL-37 for research?

In the US, LL-37 is sold strictly as a research chemical — legal to buy for laboratory research but not approved for human use. It is a synthetic antimicrobial peptide with no approved human form, sold strictly for laboratory research. The real variable isn't legality, it's quality: unverified suppliers can ship underdosed, impure, or mislabeled material. WPA records COA-related listing fields where supplied, but does not independently verify every report. Inspect the actual batch report and its laboratory, identity testing, and date before drawing conclusions. Right now that screen covers 9 LL-37 listings from 8 vendors.

How do I verify a LL-37 COA so I'm not getting an underdosed vial?

A Certificate of Analysis (COA) may report tests for a specific LL-37 batch. Check that the report identifies the compound (actually LL-37, the full 37-residue cathelicidin peptide, not a truncated fragment), names the laboratory, describes the test method and result, and matches the offered batch and date. A recorded purity value or COA-availability flag in WPA's listing data is not independent verification. Open the vendor listing and inspect the actual report before drawing conclusions. For LL-37 specifically, 8 of 9 tracked listings (89%) are marked as having COA availability in WPA's listing data; that marker is not independent verification. A purity value is separately recorded for 8 listings; purity alone does not establish identity or independent testing. The latest COA date recorded in the listing data is 8/26.

Which LL-37 vendor should I pick?

There's no single "best" LL-37 vendor — it depends on what you weigh most. WPA ranks tracked listings using recorded purity and date fields where available, visitor click activity, price, stock status, and discount data; this ranking is not independent verification of a report. LL-37 is a long 37-residue peptide whose synthesis quality varies widely between sources, so weigh assayed purity and a recent COA heavily. 8 vendors currently carry LL-37, and Ascension Peptides holds the best true value at $4.45/mg on the 10 mg listed purchase quantity. Review the actual report and confirm its batch details before making a decision.

How much does LL-37 cost — and how do I know I'm not overpaying?

Judge LL-37 by true price per milligram, not the sticker price on one vial — a cheap small vial often costs more per mg than a larger one. It most often ships in 5 mg vials, so compare $/mg across those rather than the sticker price on one vial. Tracked LL-37 listings currently run $4.45/mg to $14.25/mg across 5mg, 10mg listed purchase quantities (not necessarily single vials). WPA normalizes tracked listings to $/mg, and the live cost-per-month card estimates your spend at the most common dose. The one catch: the lowest $/mg sometimes means buying a bigger vial than your cycle needs.

How much LL-37 do I need for one full cycle?

In lifetime LL-37 calculator inputs, 200mcg is the most frequent entered amount (23 of 98 runs). Separately, Daily (7x/wk) is the most frequent overall cadence (4 of 18 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 200mcg, 5x/week is most frequent (3 of 11 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. Dividing the listed 10 mg purchase quantity by 0.2 mg gives roughly 50 nominal portions before preparation losses; vial count and stability after preparation are separate questions. A cycle requires an independently chosen amount, cadence and time horizon; calculator observations do not supply those decisions. Compare nominal package quantities and model your own selections in the cost card.

Are discount codes available for LL-37?

Participating LL-37 vendors may offer WPA researcher discount codes. Codes can change, exclude sale items or carry order minimums. 9 of the 9 tracked LL-37 listings carry a code right now, the largest worth 50% off. Each listing shows the recorded code and discounted price where available; confirm the actual package and checkout terms with the vendor.

Where can I compare LL-37 prices and listing details?

This comparison shows 9 tracked listings for LL-37 in the selected format. Compare purchase price, established nominal quantities, discount terms and recorded COA availability, purity and date fields. Those fields are not independent verification. Inspect actual batch reports and confirm package composition and checkout price on the vendor's site.